Impact Factor 6.429

The 5th most cited journal in Immunology

Correction ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.00403

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Stud

  • 1Azienda Ospedaliera Universitaria San Martino (IRCCS), Italy

Corrigendum on:
9Istituto Dermopatico dell’Immacolata IDI-IRCCS, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

Clearly state the mistake being fixed
In the original article affiliation number 9 is wrong and should be corrected as follows:
9Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
This error does not change the scientific conclusions of the article in any way.

Keywords: CTLA-4 variants, Melanoma, ipilimumab, best overall response, overall survival, predictive/prognostic factor.

Received: 15 Jan 2018; Accepted: 13 Feb 2018.

Edited by:

Matteo Bellone, San Raffaele Hospital (IRCCS), Italy

Copyright: © 2018 Pistillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Maria Pia Pistillo, Azienda Ospedaliera Universitaria San Martino (IRCCS), Genova, Italy, mariapia.pistillo@hsanmartino.it